Global Oncology Precision Medicine Market: Focus on Application Area, Ecosystem Type, Country Data (15 Countries)- Analysis and Forecast, 2020-2030
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Market Report Coverage - Oncology Precision Medicine
Market Segmentation
Abbott Laboratories, Agilent Technologies, Inc., Almac Group Ltd., ANGLE plc, Asuragen, Inc.,AstraZeneca PLC, Bristol Myers Squibb, bioMйrieux SA., BGI Group, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Gilead Sciences, Inc. Illumina, Inc, Konica Minolta, Inc., Laboratory Corporation of America Holdings, MDx Health, Inc., Myriad Genetics, Inc., Novartis AG, Opko Health,Inc., Pacific Biosciences of California, Inc.,Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics
Key Questions Answered in this Report:
Precision medicine is a concept that collectively integrates the outcomes and the endeavors of research and healthcare. The ability to tailor the diagnostics and therapeutics offered to the patients is the key to precision medicine. The combination of biotechnology development, digitization of healthcare, and public investment led to the evolution of the personalization of disease-based therapies.
This evolution within precision medicine will profoundly impact the biopharmaceutical industry, and multiple players from biopharma to diagnostics companies with multiple functions such as research and development to commercial operations will witness a change.
The global oncology precision medicine market was valued at $46.90 billion in 2019, and it is expected to grow at an impressive double-digit rate of 11.21% and reach a value of $148.66 billion in 2030.
The existing oncology precision medicine market is favored by multiple factors, which include rising cancer incidences and death rates, several government initiatives, coupled up with the general population’s growing awareness pertaining to molecular level diagnosis and treatment. Additionally, the increasing number of advancements in molecular diagnostics, increasing FDA approvals for such precision medicine-based oncology drugs, improving focus on research and development activities by key healthcare companies are also leading toward market expansion.
Within the research report, the market is segmented on the basis of application (breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, other applications), ecosystem type (applied sciences, precision diagnostics, digital health and information technology, precision therapeutics), and region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities to detail the scope and provide a 360-coverage of the domain.
Competitive Landscape
The oncology precision medicine market witnessed 78 collaborations and partnerships, four funding and investments, 45 product launches and enhancements, 22 regulatory and legal activities, 17 mergers and acquisitions, and six business expansions.
Major players within the oncology precision medicine market are Abbott Laboratories, Agilent Technologies, Inc., Almac Group Ltd., ANGLE plc, Asuragen Inc., AstraZeneca PLC, Bristol Myers Squibb, bioMйrieux SA., BGI Group, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Gilead Sciences, Inc. Illumina, Inc, Konica Minolta, Inc., Laboratory Corporation of America Holdings, MDx Health, Inc., Myriad Genetics, Inc., Novartis AG, Opko Health,Inc., Pacific Biosciences of California, Inc.,Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics.
Market Report Coverage - Oncology Precision Medicine
Market Segmentation
- By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Other Applications
- By Ecosystem: Applied Sciences, Precision Diagnostics, Digital Health and Information Technology, Precision Therapeutics
- By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World
- North America – U.S., Canada
- Europe – Germany, U.K., France, Italy, Spain, and Rest-of-Europe
- Asia-Pacific – China, Australia, Japan, India, and Rest-of-Asia-Pacific
- Latin America – Brazil, Mexico, and Rest-of-LATAM
- Rest-of-the-World
- Increasing Incidences of Cancer
- Decreasing Trial and Error-Based Drug Prescription Through Pharmacogenomics
- Rapid Technological Advancements
- Increasing Usage of Predictive Biomarker for Diagnostics
- Decreasing Cost of Genomic Sequencing
- Large Scale Data Integration, Analysis and Establishment of Secure Data Libraries
- Inadequate Reimbursement Scenario for Precision Medicine
- Regulatory Barriers in the Advancement of Precision Medicine
- Lack of Expertise, Education and Awareness for Precision Medicine Implementation
- Unprecedented Improvements in Disease Modelling via In Silico, In Vitro, and In Vivo Methods
- Expansion into the Emerging Markets
Abbott Laboratories, Agilent Technologies, Inc., Almac Group Ltd., ANGLE plc, Asuragen, Inc.,AstraZeneca PLC, Bristol Myers Squibb, bioMйrieux SA., BGI Group, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Gilead Sciences, Inc. Illumina, Inc, Konica Minolta, Inc., Laboratory Corporation of America Holdings, MDx Health, Inc., Myriad Genetics, Inc., Novartis AG, Opko Health,Inc., Pacific Biosciences of California, Inc.,Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics
Key Questions Answered in this Report:
- What are the most common causes of cancer deaths globally?
- What are the emerging technologies that can take over the current technologies for molecular diagnosis within the oncology precision medicine market?
- What is the patent expiry scenario of the key companion diagnostics-based drugs within the market?
- How are the key market players performing research investments in the respective market?
- Who are the upcoming start-ups within the oncology precision medicine market and their funding scenario?
- What are the key development strategies implemented by the key players to stand out in this market?
- How have the strategic collaborations among the key players and academia, providing a push to product development within the oncology precision medicine market?
- What are the regulations pertaining to the precision medicine in oncology among different regions and their impact over the respective market?
- What are the initiatives implemented by different government bodies regulating the development and commercialization of oncology precision medicine products and associated platforms?
- How has COVID-19 impacted the oncology precision medicine market?
- How will the urgency of the pandemic influence the global oncology precision medicine market?
- What are the leading companies dominating the global oncology precision medicine market?
- What is the reimbursement scenario of the products offered in the global oncology precision medicine market?
- Based on the application area, which global oncology precision medicine market application area is anticipated to witness a massive rise in demand in the forecast period?
- How is each segment of the global oncology precision medicine market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2030?
- How is the global oncology precision medicine industry anticipated to evolve during the forecast period 2020-2030?
- What are the leading trends and consumer preferences witnessed in the global oncology precision medicine market?
Precision medicine is a concept that collectively integrates the outcomes and the endeavors of research and healthcare. The ability to tailor the diagnostics and therapeutics offered to the patients is the key to precision medicine. The combination of biotechnology development, digitization of healthcare, and public investment led to the evolution of the personalization of disease-based therapies.
This evolution within precision medicine will profoundly impact the biopharmaceutical industry, and multiple players from biopharma to diagnostics companies with multiple functions such as research and development to commercial operations will witness a change.
The global oncology precision medicine market was valued at $46.90 billion in 2019, and it is expected to grow at an impressive double-digit rate of 11.21% and reach a value of $148.66 billion in 2030.
The existing oncology precision medicine market is favored by multiple factors, which include rising cancer incidences and death rates, several government initiatives, coupled up with the general population’s growing awareness pertaining to molecular level diagnosis and treatment. Additionally, the increasing number of advancements in molecular diagnostics, increasing FDA approvals for such precision medicine-based oncology drugs, improving focus on research and development activities by key healthcare companies are also leading toward market expansion.
Within the research report, the market is segmented on the basis of application (breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, other applications), ecosystem type (applied sciences, precision diagnostics, digital health and information technology, precision therapeutics), and region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities to detail the scope and provide a 360-coverage of the domain.
Competitive Landscape
The oncology precision medicine market witnessed 78 collaborations and partnerships, four funding and investments, 45 product launches and enhancements, 22 regulatory and legal activities, 17 mergers and acquisitions, and six business expansions.
Major players within the oncology precision medicine market are Abbott Laboratories, Agilent Technologies, Inc., Almac Group Ltd., ANGLE plc, Asuragen Inc., AstraZeneca PLC, Bristol Myers Squibb, bioMйrieux SA., BGI Group, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Gilead Sciences, Inc. Illumina, Inc, Konica Minolta, Inc., Laboratory Corporation of America Holdings, MDx Health, Inc., Myriad Genetics, Inc., Novartis AG, Opko Health,Inc., Pacific Biosciences of California, Inc.,Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics.
Executive Summary
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 SCOPE OF THE RESEARCH STUDY
2.1 Research Scope
2.2 Key Questions Answered by the Research Study
3 RESEARCH METHODOLOGY
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Selection Criteria for Company Profiles
4 MARKET OVERVIEW
4.1 Introduction
4.2 Evolution of Precision Medicine for Cancer Management and Treatment
4.3 Applications of Precision Medicine in Oncology
4.3.1 Identifying Genetic Mutations and Risks of Cancer Through Precision Diagnostics
4.3.2 Promising Technological Developments Supporting Precision Oncology
4.3.2.1 Low-Throughput Genomic Sequencing to High-Throughput Genomic Sequencing
4.3.2.2 Multicell Hybrid Detection to Single-Cell Precision Detection
4.3.2.3 Advancing Applications of ctDNA Detection Technology
4.3.2.4 CRISPR/Cas Technology
5 IMPACT OF COVID-19 PANDEMIC ON GLOBAL ONCOLOGY PRECISION MEDICINE MARKET
5.1 Disruption of Oncology Precision Medicine Due to COVID-19
5.2 COVID-19 Affecting Supply Chain of Oncology Precision Medicine-Based Therapies
5.3 Interruption in Research and Clinical Development and Commercial Operation
5.3.1 Research and Clinical Development
5.3.2 Commercial Operation and Access
5.4 Navigating Crisis Recovery and Looking to the Future
6 GLOBAL ONCOLOGY PRECISION MEDICINE MARKET: INDUSTRY ANALYSIS
6.1 Legal and Regulatory Framework and Requirements
6.1.1 North America
6.1.1.1 Regulatory Requirements in U.S.
6.1.2 Europe
6.1.3 Asia-Pacific
6.2 Legal Requirements and Framework by the MHLW
6.3 Patent Landscape
7 GLOBAL ONCOLOGY PRECISION MEDICINE MARKET: MARKET DYNAMICS
7.1 Overview
7.2 Market Driving Factors
7.2.1 Increasing Incidences of Cancer
7.2.2 Decreasing Trial and Error-Based Drug Prescription Through Pharmacogenomics
7.2.3 Increasing Usage of Predictive Biomarker for Diagnostics
7.2.4 Rapid Technological Advancements
7.2.5 Decreasing Cost of Genomic Sequencing
7.3 Market Restraining Factors
7.3.1 Large Scale Data Integration, Analysis and Establishment of Secure Data Libraries
7.3.2 Inadequate Reimbursement Scenario for Precision Medicine
7.3.3 Regulatory Barriers in the Advancement of Precision Medicine
7.3.4 Lack of Expertise, Education, and Awareness for Precision Medicine Implementation
7.4 Market Opportunities
7.4.1 Unprecedented Improvements in Disease Modelling via In Silico, In Vitro, and In Vivo Methods
7.4.2 Expansion into the Emerging Markets
8 GLOBAL ONCOLOGY PRECISION MEDICINE MARKET: COMPETITIVE LANDSCAPE
8.1 Key Strategies and Developments
8.1.1 Product Offerings
8.1.2 Synergistic Activities
8.1.3 Regulatory and Legal
8.1.4 Mergers and Acquisitions
8.1.5 Business Expansions and Funding
8.2 Market Share Analysis
8.3 Growth-Share Analysis (by Company), 2019
9 GLOBAL ONCOLOGY PRECISION MEDICINE MARKET (BY APPLICATION), $MILLION, 2019-2030
9.1 Overview
9.1.1 Breast Cancer
9.1.2 Lung Cancer
9.1.3 Colorectal Cancer
9.1.4 Prostate Cancer
9.1.5 Cervical Cancer
9.1.6 Other Cancer
10 GLOBAL ONCOLOGY PRECISION MEDICINE MARKET (BY ECOSYSTEM), $MILLION, 2019-2030
10.1 Overview
10.2 Applied Sciences
10.2.1 Genomics
10.2.2 Global Oncology Precision Medicine Genomics Market (by Technology)
10.2.2.1 Polymerase Chain Reaction (PCR)
10.2.2.2 Precision Medicine Next-Generation Sequencing (PM NGS)
10.2.2.3 Genome Editing
10.2.2.4 Other Technologies
10.2.3 Pharmacogenomics
10.2.4 Other Applied Sciences
10.3 Precision Diagnostics
10.3.1 Molecular Diagnostics (MDx)
10.3.2 Medical Imaging
10.4 Digital Health and Information Technology
10.4.1 Clinical Decision Support Systems (CDSS)
10.4.2 Big Data Analytics
10.4.3 IT Infrastructure
10.4.4 Genomics Informatics
10.4.5 In-Silico Informatics
10.4.6 Mobile Health
10.5 Precision Therapeutics
10.5.1 Clinical Trials
10.5.2 Cell Therapy
10.5.3 Drug Discovery and Research
10.5.4 Gene Therapy
11 GLOBAL ONCOLOGY PRECISION MEDICINE MARKET (BY REGION), $MILLION, 2019-2030
11.1 Overview
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Europe Oncology Precision Medicine Market Dynamics
11.3.2 Germany
11.3.3 France
11.3.4 Italy
11.3.5 U.K.
11.3.6 Spain
11.3.7 Rest-of-Europe
11.4 Asia-Pacific (APAC)
11.4.1 Asia-Pacific Oncology Precision Medicine Market Dynamics
11.4.1.1 China
11.4.1.2 Japan
11.4.1.3 Australia
11.4.1.4 India
11.4.1.5 Rest-of-Asia-Pacific
11.5 Latin America
11.5.1.1 Brazil
11.5.1.2 Mexico
11.5.1.3 Rest-of-LATAM
11.6 Rest-of-the-World
12 COMPANY PROFILES
12.1 Abbott Laboratories
12.1.1 Company Overview
12.1.2 Role of Abbott Laboratories in Global Oncology Precision Medicine Market
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Agilent Technologies, Inc.
12.2.1 Company Overview
12.2.2 Role of Agilent Technologies, Inc. in Global Oncology Precision Medicine Market
12.2.3 Financials
12.2.4 SWOT Analysis
12.3 Almac Group Ltd.
12.3.1 Company Overview
12.3.2 Role of Almac Group Ltd. in Global Oncology Precision Medicine Market
12.3.3 SWOT Analysis
12.4 ANGLE plc
12.4.1 Company Overview
12.4.2 Role of ANGLE plc in the Global Oncology Precision Medicine Market
12.4.3 Financials
12.4.4 Key Insights About Financial Health of the Company
12.4.5 SWOT Analysis
12.5 ASURAGEN INC.
12.5.1 Company Overview
12.5.2 Role of ASURAGEN Inc. in Global Oncology Precision Medicine Market
12.5.3 SWOT Analysis
12.6 BGI Group
12.6.1 Company Overview
12.6.2 Role of BGI Group in Global Oncology Precision Medicine Market
12.6.3 SWOT Analysis
12.7 Bio-Rad Laboratories, Inc.
12.7.1 Company Overview
12.7.2 Role of Bio-Rad Laboratories, Inc.in Global Oncology Precision Medicine Market
12.7.3 Financials
12.7.4 SWOT Analysis
12.8 bioMйrieux S.A.
12.8.1 Company Overview
12.8.2 Role of bioMйrieux SA. in Global Oncology Precision Medicine Market
12.8.3 Financials
12.8.4 SWOT Analysis
12.9 Bristol-Myers Squibb Company
12.9.1 Company Overview
12.9.2 Role of Bristol-Myers Squibb Company in Global Oncology Precision Medicine Market
12.9.3 Financials
12.9.4 SWOT Analysis
12.1 F. Hoffmann-La Roche Ltd
12.10.1 Company Overview
12.10.2 Role of F. Hoffman-LA Roche Ltd in Global Oncology Precision Medicine Market
12.10.3 Financials
12.10.4 SWOT Analysis
12.11 Gilead Sciences, Inc.
12.11.1 Company Overview
12.11.2 Role of Gilead Sciences, Inc. in Global Oncology Precision Medicine Market
12.11.3 Financials
12.11.4 SWOT Analysis
12.12 Illumina, Inc.
12.12.1 Company Overview
12.12.2 Role of Illumina, Inc. in Global Oncology Precision Medicine Market
12.12.3 Financials
12.12.4 SWOT Analysis
12.13 Konica Minolta, Inc.
12.13.1 Company Overview
12.13.2 Role of Konica Minolta, Inc. in Global Oncology Precision Medicine Market
12.13.3 Financials
12.13.4 SWOT Analysis
12.14 Laboratory Corporation of America Holdings
12.14.1 Company Overview
12.14.2 Role of Laboratory Corporation of America Holdings in Global Oncology Precision Medicine Market
12.14.3 Financials
12.14.4 SWOT Analysis
12.15 MDx Health, Inc.
12.15.1 Company Overview
12.15.2 Role of MDx Health, Inc. in the Global Precision Medicine Market
12.15.3 Financials
12.15.4 SWOT Analysis
12.16 Myriad Genetics, Inc
12.16.1 Company Overview
12.16.2 Role of Myriad Genetics, Inc. in the Global Oncology Precision Medicine Market
12.16.3 Financials
12.16.4 Key Insights About Financial Health of the Company
12.16.5 SWOT Analysis
12.17 Novartis AG
12.17.1 Company overview
12.17.2 Role of Novartis AG in the Global Oncology Precision Medicine Market
12.17.3 Financials
12.17.4 Key Insights About Financial Health of the Company
12.17.5 SWOT Analysis
12.18 OPKO Health, Inc.
12.18.1 Company Overview
12.18.2 Role of OPKO Health, Inc. in Global Oncology Precision Medicine Market
12.18.3 Financials
12.18.4 SWOT Analysis
12.19 Pacific Biosciences of California, Inc.
12.19.1 Company Overview
12.19.2 Role of Pacific Biosciences of California, Inc. in the Global Oncology Precision Medicine Market
12.19.3 Financials
12.19.4 Key Insights About Financial Health of the Company
12.19.5 SWOT Analysis
12.2 Quest Diagnostics
12.20.1 Company Overview
12.20.2 Role of Quest Diagnostics in Global Oncology Precision Medicine Market
12.20.3 Financials
12.20.4 SWOT Analysis
12.21 QIAGEN N.V.*
12.21.1 Company Overview
12.21.2 Role of QIAGEN N.V. in Global Oncology Precision Medicine Market
12.21.3 Financials
12.21.4 SWOT Analysis
12.22 Thermo Fisher Scientific Inc.
12.22.1 Company Overview
12.22.2 Role of Thermo Fisher Scientific Inc. in Global Oncology Precision Medicine Market
12.22.3 Financials
12.22.4 SWOT Analysis
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 SCOPE OF THE RESEARCH STUDY
2.1 Research Scope
2.2 Key Questions Answered by the Research Study
3 RESEARCH METHODOLOGY
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Selection Criteria for Company Profiles
4 MARKET OVERVIEW
4.1 Introduction
4.2 Evolution of Precision Medicine for Cancer Management and Treatment
4.3 Applications of Precision Medicine in Oncology
4.3.1 Identifying Genetic Mutations and Risks of Cancer Through Precision Diagnostics
4.3.2 Promising Technological Developments Supporting Precision Oncology
4.3.2.1 Low-Throughput Genomic Sequencing to High-Throughput Genomic Sequencing
4.3.2.2 Multicell Hybrid Detection to Single-Cell Precision Detection
4.3.2.3 Advancing Applications of ctDNA Detection Technology
4.3.2.4 CRISPR/Cas Technology
5 IMPACT OF COVID-19 PANDEMIC ON GLOBAL ONCOLOGY PRECISION MEDICINE MARKET
5.1 Disruption of Oncology Precision Medicine Due to COVID-19
5.2 COVID-19 Affecting Supply Chain of Oncology Precision Medicine-Based Therapies
5.3 Interruption in Research and Clinical Development and Commercial Operation
5.3.1 Research and Clinical Development
5.3.2 Commercial Operation and Access
5.4 Navigating Crisis Recovery and Looking to the Future
6 GLOBAL ONCOLOGY PRECISION MEDICINE MARKET: INDUSTRY ANALYSIS
6.1 Legal and Regulatory Framework and Requirements
6.1.1 North America
6.1.1.1 Regulatory Requirements in U.S.
6.1.2 Europe
6.1.3 Asia-Pacific
6.2 Legal Requirements and Framework by the MHLW
6.3 Patent Landscape
7 GLOBAL ONCOLOGY PRECISION MEDICINE MARKET: MARKET DYNAMICS
7.1 Overview
7.2 Market Driving Factors
7.2.1 Increasing Incidences of Cancer
7.2.2 Decreasing Trial and Error-Based Drug Prescription Through Pharmacogenomics
7.2.3 Increasing Usage of Predictive Biomarker for Diagnostics
7.2.4 Rapid Technological Advancements
7.2.5 Decreasing Cost of Genomic Sequencing
7.3 Market Restraining Factors
7.3.1 Large Scale Data Integration, Analysis and Establishment of Secure Data Libraries
7.3.2 Inadequate Reimbursement Scenario for Precision Medicine
7.3.3 Regulatory Barriers in the Advancement of Precision Medicine
7.3.4 Lack of Expertise, Education, and Awareness for Precision Medicine Implementation
7.4 Market Opportunities
7.4.1 Unprecedented Improvements in Disease Modelling via In Silico, In Vitro, and In Vivo Methods
7.4.2 Expansion into the Emerging Markets
8 GLOBAL ONCOLOGY PRECISION MEDICINE MARKET: COMPETITIVE LANDSCAPE
8.1 Key Strategies and Developments
8.1.1 Product Offerings
8.1.2 Synergistic Activities
8.1.3 Regulatory and Legal
8.1.4 Mergers and Acquisitions
8.1.5 Business Expansions and Funding
8.2 Market Share Analysis
8.3 Growth-Share Analysis (by Company), 2019
9 GLOBAL ONCOLOGY PRECISION MEDICINE MARKET (BY APPLICATION), $MILLION, 2019-2030
9.1 Overview
9.1.1 Breast Cancer
9.1.2 Lung Cancer
9.1.3 Colorectal Cancer
9.1.4 Prostate Cancer
9.1.5 Cervical Cancer
9.1.6 Other Cancer
10 GLOBAL ONCOLOGY PRECISION MEDICINE MARKET (BY ECOSYSTEM), $MILLION, 2019-2030
10.1 Overview
10.2 Applied Sciences
10.2.1 Genomics
10.2.2 Global Oncology Precision Medicine Genomics Market (by Technology)
10.2.2.1 Polymerase Chain Reaction (PCR)
10.2.2.2 Precision Medicine Next-Generation Sequencing (PM NGS)
10.2.2.3 Genome Editing
10.2.2.4 Other Technologies
10.2.3 Pharmacogenomics
10.2.4 Other Applied Sciences
10.3 Precision Diagnostics
10.3.1 Molecular Diagnostics (MDx)
10.3.2 Medical Imaging
10.4 Digital Health and Information Technology
10.4.1 Clinical Decision Support Systems (CDSS)
10.4.2 Big Data Analytics
10.4.3 IT Infrastructure
10.4.4 Genomics Informatics
10.4.5 In-Silico Informatics
10.4.6 Mobile Health
10.5 Precision Therapeutics
10.5.1 Clinical Trials
10.5.2 Cell Therapy
10.5.3 Drug Discovery and Research
10.5.4 Gene Therapy
11 GLOBAL ONCOLOGY PRECISION MEDICINE MARKET (BY REGION), $MILLION, 2019-2030
11.1 Overview
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Europe Oncology Precision Medicine Market Dynamics
11.3.2 Germany
11.3.3 France
11.3.4 Italy
11.3.5 U.K.
11.3.6 Spain
11.3.7 Rest-of-Europe
11.4 Asia-Pacific (APAC)
11.4.1 Asia-Pacific Oncology Precision Medicine Market Dynamics
11.4.1.1 China
11.4.1.2 Japan
11.4.1.3 Australia
11.4.1.4 India
11.4.1.5 Rest-of-Asia-Pacific
11.5 Latin America
11.5.1.1 Brazil
11.5.1.2 Mexico
11.5.1.3 Rest-of-LATAM
11.6 Rest-of-the-World
12 COMPANY PROFILES
12.1 Abbott Laboratories
12.1.1 Company Overview
12.1.2 Role of Abbott Laboratories in Global Oncology Precision Medicine Market
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Agilent Technologies, Inc.
12.2.1 Company Overview
12.2.2 Role of Agilent Technologies, Inc. in Global Oncology Precision Medicine Market
12.2.3 Financials
12.2.4 SWOT Analysis
12.3 Almac Group Ltd.
12.3.1 Company Overview
12.3.2 Role of Almac Group Ltd. in Global Oncology Precision Medicine Market
12.3.3 SWOT Analysis
12.4 ANGLE plc
12.4.1 Company Overview
12.4.2 Role of ANGLE plc in the Global Oncology Precision Medicine Market
12.4.3 Financials
12.4.4 Key Insights About Financial Health of the Company
12.4.5 SWOT Analysis
12.5 ASURAGEN INC.
12.5.1 Company Overview
12.5.2 Role of ASURAGEN Inc. in Global Oncology Precision Medicine Market
12.5.3 SWOT Analysis
12.6 BGI Group
12.6.1 Company Overview
12.6.2 Role of BGI Group in Global Oncology Precision Medicine Market
12.6.3 SWOT Analysis
12.7 Bio-Rad Laboratories, Inc.
12.7.1 Company Overview
12.7.2 Role of Bio-Rad Laboratories, Inc.in Global Oncology Precision Medicine Market
12.7.3 Financials
12.7.4 SWOT Analysis
12.8 bioMйrieux S.A.
12.8.1 Company Overview
12.8.2 Role of bioMйrieux SA. in Global Oncology Precision Medicine Market
12.8.3 Financials
12.8.4 SWOT Analysis
12.9 Bristol-Myers Squibb Company
12.9.1 Company Overview
12.9.2 Role of Bristol-Myers Squibb Company in Global Oncology Precision Medicine Market
12.9.3 Financials
12.9.4 SWOT Analysis
12.1 F. Hoffmann-La Roche Ltd
12.10.1 Company Overview
12.10.2 Role of F. Hoffman-LA Roche Ltd in Global Oncology Precision Medicine Market
12.10.3 Financials
12.10.4 SWOT Analysis
12.11 Gilead Sciences, Inc.
12.11.1 Company Overview
12.11.2 Role of Gilead Sciences, Inc. in Global Oncology Precision Medicine Market
12.11.3 Financials
12.11.4 SWOT Analysis
12.12 Illumina, Inc.
12.12.1 Company Overview
12.12.2 Role of Illumina, Inc. in Global Oncology Precision Medicine Market
12.12.3 Financials
12.12.4 SWOT Analysis
12.13 Konica Minolta, Inc.
12.13.1 Company Overview
12.13.2 Role of Konica Minolta, Inc. in Global Oncology Precision Medicine Market
12.13.3 Financials
12.13.4 SWOT Analysis
12.14 Laboratory Corporation of America Holdings
12.14.1 Company Overview
12.14.2 Role of Laboratory Corporation of America Holdings in Global Oncology Precision Medicine Market
12.14.3 Financials
12.14.4 SWOT Analysis
12.15 MDx Health, Inc.
12.15.1 Company Overview
12.15.2 Role of MDx Health, Inc. in the Global Precision Medicine Market
12.15.3 Financials
12.15.4 SWOT Analysis
12.16 Myriad Genetics, Inc
12.16.1 Company Overview
12.16.2 Role of Myriad Genetics, Inc. in the Global Oncology Precision Medicine Market
12.16.3 Financials
12.16.4 Key Insights About Financial Health of the Company
12.16.5 SWOT Analysis
12.17 Novartis AG
12.17.1 Company overview
12.17.2 Role of Novartis AG in the Global Oncology Precision Medicine Market
12.17.3 Financials
12.17.4 Key Insights About Financial Health of the Company
12.17.5 SWOT Analysis
12.18 OPKO Health, Inc.
12.18.1 Company Overview
12.18.2 Role of OPKO Health, Inc. in Global Oncology Precision Medicine Market
12.18.3 Financials
12.18.4 SWOT Analysis
12.19 Pacific Biosciences of California, Inc.
12.19.1 Company Overview
12.19.2 Role of Pacific Biosciences of California, Inc. in the Global Oncology Precision Medicine Market
12.19.3 Financials
12.19.4 Key Insights About Financial Health of the Company
12.19.5 SWOT Analysis
12.2 Quest Diagnostics
12.20.1 Company Overview
12.20.2 Role of Quest Diagnostics in Global Oncology Precision Medicine Market
12.20.3 Financials
12.20.4 SWOT Analysis
12.21 QIAGEN N.V.*
12.21.1 Company Overview
12.21.2 Role of QIAGEN N.V. in Global Oncology Precision Medicine Market
12.21.3 Financials
12.21.4 SWOT Analysis
12.22 Thermo Fisher Scientific Inc.
12.22.1 Company Overview
12.22.2 Role of Thermo Fisher Scientific Inc. in Global Oncology Precision Medicine Market
12.22.3 Financials
12.22.4 SWOT Analysis
LIST OF TABLES
Table 9.1: Estimated New Cancer Cases and Deaths,United States, 2020
Table 10.1: List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labelling
Table 9.1: Estimated New Cancer Cases and Deaths,United States, 2020
Table 10.1: List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labelling
LIST OF FIGURES
Figure 1: Overall Deaths due to Key Cancer Causes, in Millions, (2012-2019)
Figure 2: Global Oncology Precision Medicine Market, 2019-2030
Figure 3: Market Drivers, Opportunities, and Restraints
Figure 4: Share of Key Developments and Strategies, January 2016-November 2020
Figure 5: Growth-Share Matrix for Global Oncology Precision Medicine Market (by Company), 2019
Figure 6: Global Oncology Precision Medicine Applications Market Share (Application Type), 2019-2030
Figure 7: Global Oncology Precision Medicine Market (by Region)
Figure 2.1: Global Oncology Precision Medicine Market Segmentation
Figure 3.1: Global Oncology Precision Medicine Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Share of Total Number of Companies Profiled
Figure 4.1: Global Oncology Precision Medicine Market, 2019-2030
Figure 4.2: Evolution of Precision Medicine Technology
Figure 4.3: Molecular Diagnostics in Oncology
Figure 5.1: Number of Cancer Cases Diagnosed in the Netherlands (January 3, 2020, to April 12, 2020)
Figure 5.2: Pre-COVID-19 and Post-COVID-19 Scenario of Global Oncology Precision Medicine Market, 2017-2025
Figure 5.3: Areas of Disruption in Clinical Development
Figure 5.4: Measure to Navigate Crisis Recovery
Figure 6.1: FDA Guidelines for CDx Approval
Figure 6.2: Share of Patents Assigned (2015-2019)
Figure 6.3: Total Number of Patents Assigned to Key Technologies, 2016-2018
Figure 7.1: Impact Analysis of Market Dynamics
Figure 7.2: Rising Incidences of Cancer (2015 and 2018)
Figure 7.3: Estimated Cancer Incidences (Region-Wise), 2018 and 2040
Figure 7.4: Variable Outcomes of Pharmacologically Active Oncology Drugs and Prodrugs
Figure 7.5: Role of Biomarkers in Different Stages of Cancer
Figure 7.6: Significance of Biomarker on Treatment Monitoring
Figure 8.1: Share of Key Developments and Strategies, January 2016-November 2020
Figure 8.2: Share of Product Offerings, January 2016-August 2020
Figure 8.3: Share of Synergistic Activities, January 2016-August 2020
Figure 8.4: Share of Regulatory and Legal, January 2016-August 2020
Figure 8.5: Share of Mergers and Acquisitions, January 2016-August 2020
Figure 8.6: Share of Mergers and Acquisitions, January 2016-August 2020
Figure 8.7: Market Share Analysis: Global Oncology Precision Medicine Market, 2019
Figure 8.8: Growth-Share Matrix for Global Oncology Precision Medicine Market (by Company), 2019
Figure 9.1: Global Oncology Precision Medicine Market Share (by Application Type), 2019-2030
Figure 9.2: Global Oncology Precision Medicine Market (by Breast Cancer), 2019-2030
Figure 9.3: Global Oncology Precision Medicine Market (by Lung Cancer), 2019-2030
Figure 9.4: Global Oncology Precision Medicine Market (by Colorectal Cancer), 2019-2030
Figure 9.5: Global Oncology Precision Medicine Market (by Prostate Cancer), 2019-2030
Figure 9.6: Global Oncology Precision Medicine Market (by Cervical Cancer), 2019-2030
Figure 9.7: Global Oncology Precision Medicine Market (by Other Cancer), 2019-2030
Figure 10.1: Global Oncology Precision Medicine Market (by Ecosystem)
Figure 10.2: Precision Medicine: The Ecosystem
Figure 10.3: Global Oncology Precision Medicine Market (by Applied Sciences)
Figure 10.4: Global Oncology Precision Medicine Market (by Applied Sciences), 2019-2030
Figure 10.5: Global Oncology Precision Medicine Applied Sciences Market Share (by Type), 2019-2030
Figure 10.6: Global Oncology Precision Medicine Genomics Market, 2019-2030
Figure 10.7: Global Oncology Precision Medicine Genomics Market Share (by Technology)
Figure 10.8: Global Oncology Precision Medicine PCR Market, 2019-2030
Figure 10.9: Global Oncology Precision Medicine NGS Market, 2019-2030
Figure 10.10: Global Oncology Precision Medicine Genome Editing Market, 2019-2030
Figure 10.11: Global Oncology Precision Medicine Other Technologies Market, 2019-2030
Figure 10.12: Global Oncology Precision Medicine Pharmacogenomics Market, 2019-2030
Figure 10.13: Global Oncology Precision Medicine Other Applied Sciences Market, 2019-2030
Figure 10.14: Global Oncology Precision Medicine Market (by Precision Diagnostics)
Figure 10.15: Global Oncology Precision Medicine Market (by Precision Diagnostics), 2019-2030
Figure 10.16: Global Oncology Precision Medicine Diagnostics Market Share (by Type), 2019-2030
Figure 10.17: Global Oncology Precision Medicine Molecular Diagnostics Market, 2019-2030
Figure 10.18: Global Oncology Precision Medicine Medical Imaging Market, 2019-2030
Figure 10.19: Global Oncology Precision Medicine Digital Health and Information Technology Market, 2019-2030
Figure 10.20: Global Oncology Precision Medicine Digital Health and Information Technology Market Share (by Type), 2019-2030
Figure 10.21: Global Oncology Precision Medicine CDSS Market, 2019-2030
Figure 10.22: Global Oncology Precision Medicine Big Data Analytics Market, 2019-2030
Figure 10.23: Global Oncology Precision Medicine IT Infrastructure Market, 2019-2030
Figure 10.24: Global Oncology Precision Medicine Genomics Informatics Market, 2019-2030
Figure 10.25: Global Oncology Precision Medicine In-Silico Informatics Market, 2019-2030
Figure 10.26: Global Oncology Precision Medicine Mobile Health Market, 2019-2030
Figure 10.27: Global Oncology Precision Medicine Therapeutics Market, 2019-2030
Figure 10.28: Global Oncology Precision Medicine Therapeutics Market Share (by Type), 2019-2030
Figure 10.29: Global Oncology Precision Medicine Clinical Trials Market, 2019-2030
Figure 10.30: Global Oncology Precision Medicine Cell Therapy Market, 2019-2030
Figure 10.31: Global Oncology Precision Medicine Drug Discovery and Research Market, 2019-2030
Figure 10.32: Types of Gene Therapy
Figure 10.33: Global Oncology Precision Medicine Gene Therapy Market, 2019-2030
Figure 11.1: Global Oncology Precision Medicine Market (by Region)
Figure 11.2: North America Global Oncology Precision Medicine Market, 2019-2030
Figure 11.3: North America: Market Dynamics
Figure 11.4: North America Global Oncology Precision Medicine Market (by Country), 2019-2030
Figure 11.5: U.S. Oncology Precision Medicine Market, 2019-2030
Figure 11.6: Canada Oncology Precision Medicine Market, 2019-2030
Figure 11.7: Europe Oncology Precision Medicine Market, 2019-2030
Figure 11.8: Europe: Market Dynamics
Figure 11.9: Europe Oncology Precision Medicine Market (by Country), 2019-2030
Figure 11.10: Germany Oncology Precision Medicine Market, 2019-2030
Figure 11.11: France Oncology Precision Medicine Market, 2019-2030
Figure 11.12: Italy Oncology Precision Medicine Market, 2019-2030
Figure 11.13: U.K. Oncology Precision Medicine Market, 2019-2030
Figure 11.14: Spain Oncology Precision Medicine Market, 2019-2030
Figure 11.15: Rest-of-Europe Oncology Precision Medicine Market, 2019-2030
Figure 11.16: Asia-Pacific Oncology Precision Medicine Market, 2019-2030
Figure 11.17: Asia-Pacific: Market Dynamics
Figure 11.18: Asia-Pacific Oncology Precision Medicine Market (by Country), 2019-2030
Figure 11.19: China Oncology Precision Medicine Market, 2019-2030
Figure 11.20: Japan Oncology Precision Medicine Market, 2019-2030
Figure 11.21: Australia Oncology Precision Medicine Market, 2019-2030
Figure 11.22: India Oncology Precision Medicine Market, 2019-2030
Figure 11.23: Rest-of-Asia-Pacific Oncology Precision Medicine Market, 2019-2030
Figure 11.24: Latin America Oncology Precision Medicine Market, 2019-2030
Figure 11.25: Latin America: Market Dynamics
Figure 11.26: Latin America Global Oncology Precision Medicine Market (by Country), 2019 and 2030
Figure 11.27: Brazil Oncology Precision Medicine Market, 2019-2030
Figure 11.28: Mexico Oncology Precision Medicine Market, 2019-2030
Figure 11.29: Rest-of-LATAM Oncology Precision Medicine Market, 2019-2030
Figure 11.30: Rest-of-the-World Oncology Precision Medicine Market, 2019-2030
Figure 12.1: Abbott Laboratories: Overall Product Offerings
Figure 12.2: Abbott Laboratories: Overall Financials, 2017-2019
Figure 12.3: Abbott Laboratories: Net Revenue (by Business Segment), 2017-2019
Figure 12.4: Abbott Laboratories: Net Revenue (by Region), 2017-2019
Figure 12.5: Abbott Laboratories: Research and Development Expense, 2017-2019
Figure 12.6: Abbott Laboratories: SWOT Analysis
Figure 12.7: Agilent Technologies, Inc.: Overall Product Offerings
Figure 12.8: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 12.9: Agilent Technologies, Inc.: Net Revenue (by Business Segment), 2017-2019
Figure 12.10: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.11: Agilent Technologies, Inc.: Research and Development Expense, 2017-2019
Figure 12.12: Agilent Technologies, Inc.: SWOT Analysis
Figure 12.13: Almac Group Ltd.: Overall Product Offerings
Figure 12.14: Almac Group Ltd.: SWOT Analysis
Figure 12.15: ANGLE plc: Overall Financials, 2017-2019
Figure 12.16: ANGLE plc: Revenue (by Region), 2018-2019
Figure 12.17: ANGLE plc R&D Expenditure, 2017-2019
Figure 12.18: ANGLE plc: SWOT Analysis
Figure 12.19: ASURAGEN, INC.: Overall Product Offerings
Figure 12.20: ASURAGEN INC.: SWOT Analysis
Figure 12.21: BGI Group.: Overall Product Portfolio
Figure 12.22: BGI Group: SWOT Analysis
Figure 12.23: Bio-Rad Laboratories, Inc: Overall Product Offerings
Figure 12.24: Bio-Rad Laboratories, Inc: Overall Financials, 2017-2019
Figure 12.25: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2017-2019
Figure 12.26: Bio-Rad Laboratories, Inc: Revenue (by Region), 2017-2019
Figure 12.27: Bio-Rad Laboratories, Inc. R&D Expenditure, 2017-2019
Figure 12.28: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 12.29: bioMйrieux S.A.: Overall Product Portfolio
Figure 12.30: bioMйrieux S.A.: Overall Financials, 2017-2019
Figure 12.31: bioMйrieux S.A.: Revenue (by Segment), 2017-2019
Figure 12.32: bioMйrieux S.A.: Revenue (by Region), 2018 and 2019
Figure 12.33: bioMйrieux S.A.: SWOT Analysis
Figure 12.34: Bristol-Myers Squibb Company: Overall Product Portfolio
Figure 12.35: Bristol-Myers Squibb Company: Overall Financials, 2017-2019
Figure 12.36: Bristol-Myers Squibb Company R&D Expenditure, 2017-2019
Figure 12.37: Bristol-Myers Squibb Company: SWOT Analysis
Figure 12.38: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 12.39: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 12.40: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 12.41: Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 12.42: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 12.43: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 12.44: Gilead Sciences, Inc.: Overall Product Portfolio
Figure 12.45: Gilead Sciences, Inc.: Overall Financials, 2017-2019
Figure 12.46: Gilead Sciences, Inc.: R&D Expenditure, 2017-2019
Figure 12.47: Gilead Science, Inc.: SWOT Analysis
Figure 12.48: Illumina, Inc.: Overall Product Portfolio
Figure 12.49: Illumina, Inc.: Overall Financials, 2017-2019
Figure 12.50: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 12.51: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 12.52: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 12.53: Illumina, Inc.: SWOT Analysis
Figure 12.54: Konica Minolta, Inc.: Overall Product Portfolio
Figure 12.55: Konica Minolta, Inc.: Overall Financials, 2017-2019
Figure 12.56: Konica Minolta, Inc.: Revenue (by Region), 2017-2019
Figure 12.57: Konica Minolta, Inc.: Research and Development Expense, 2017-2019
Figure 12.58: Konica Minolta, Inc.: SWOT Analysis
Figure 12.59: Laboratory Corporation of America Holdings.: Overall Product Portfolio
Figure 12.60: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 12.61: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 12.62: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 12.63: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 12.64: MDx Health, Inc.: Overall Financials, 2017--2019
Figure 12.65: MDx Health, Inc.: SWOT Analysis
Figure 12.66: Myriad Genetics, Inc.: Product Portfolio
Figure 12.67: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 12.68: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.69: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 12.70: Myriad Genetics, Inc.: SWOT Analysis
Figure 12.71: Novartis AG: Overall Product Portfolio
Figure 12.72: Novartis AG: Overall Financials, 2017-2019
Figure 12.73: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 12.74: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 12.75: Novartis AG: R& D Expense, 2017-2019
Figure 12.76: Novartis AG: SWOT Analysis
Figure 12.77: OPKO Health, Inc.: Overall Product Portfolio
Figure 12.78: OPKO Health, Inc.: Overall Financials, 2017-2019
Figure 12.79: OPKO Health, Inc: Net Revenue (by Business Segment), 2017-2019
Figure 12.80: OPKO Health, Inc.: Net Revenue (by Region), 2017-2019
Figure 12.81: OPKO Health, Inc.: Research and Development Expense, 2017-2019
Figure 12.82: OPKO Health, Inc.: SWOT Analysis
Figure 12.83: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 12.84: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
Figure 12.85: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019
Figure 12.86: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
Figure 12.87: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
Figure 12.88: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 12.89: Quest Diagnostics Incorporated: Overall Product Offerings
Figure 12.90: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 12.91: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
Figure 12.92: Quest Diagnostics Incorporated: SWOT Analysis
Figure 12.93: QIAGEN N.V.: Overall Product Portfolio
Figure 12.94: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 12.95: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 12.96: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 12.97: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 12.98: QIAGEN N.V.: SWOT Analysis
Figure 12.99: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 12.100: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 12.101: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
Figure 12.102: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 12.103: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 12.104: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 1: Overall Deaths due to Key Cancer Causes, in Millions, (2012-2019)
Figure 2: Global Oncology Precision Medicine Market, 2019-2030
Figure 3: Market Drivers, Opportunities, and Restraints
Figure 4: Share of Key Developments and Strategies, January 2016-November 2020
Figure 5: Growth-Share Matrix for Global Oncology Precision Medicine Market (by Company), 2019
Figure 6: Global Oncology Precision Medicine Applications Market Share (Application Type), 2019-2030
Figure 7: Global Oncology Precision Medicine Market (by Region)
Figure 2.1: Global Oncology Precision Medicine Market Segmentation
Figure 3.1: Global Oncology Precision Medicine Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Share of Total Number of Companies Profiled
Figure 4.1: Global Oncology Precision Medicine Market, 2019-2030
Figure 4.2: Evolution of Precision Medicine Technology
Figure 4.3: Molecular Diagnostics in Oncology
Figure 5.1: Number of Cancer Cases Diagnosed in the Netherlands (January 3, 2020, to April 12, 2020)
Figure 5.2: Pre-COVID-19 and Post-COVID-19 Scenario of Global Oncology Precision Medicine Market, 2017-2025
Figure 5.3: Areas of Disruption in Clinical Development
Figure 5.4: Measure to Navigate Crisis Recovery
Figure 6.1: FDA Guidelines for CDx Approval
Figure 6.2: Share of Patents Assigned (2015-2019)
Figure 6.3: Total Number of Patents Assigned to Key Technologies, 2016-2018
Figure 7.1: Impact Analysis of Market Dynamics
Figure 7.2: Rising Incidences of Cancer (2015 and 2018)
Figure 7.3: Estimated Cancer Incidences (Region-Wise), 2018 and 2040
Figure 7.4: Variable Outcomes of Pharmacologically Active Oncology Drugs and Prodrugs
Figure 7.5: Role of Biomarkers in Different Stages of Cancer
Figure 7.6: Significance of Biomarker on Treatment Monitoring
Figure 8.1: Share of Key Developments and Strategies, January 2016-November 2020
Figure 8.2: Share of Product Offerings, January 2016-August 2020
Figure 8.3: Share of Synergistic Activities, January 2016-August 2020
Figure 8.4: Share of Regulatory and Legal, January 2016-August 2020
Figure 8.5: Share of Mergers and Acquisitions, January 2016-August 2020
Figure 8.6: Share of Mergers and Acquisitions, January 2016-August 2020
Figure 8.7: Market Share Analysis: Global Oncology Precision Medicine Market, 2019
Figure 8.8: Growth-Share Matrix for Global Oncology Precision Medicine Market (by Company), 2019
Figure 9.1: Global Oncology Precision Medicine Market Share (by Application Type), 2019-2030
Figure 9.2: Global Oncology Precision Medicine Market (by Breast Cancer), 2019-2030
Figure 9.3: Global Oncology Precision Medicine Market (by Lung Cancer), 2019-2030
Figure 9.4: Global Oncology Precision Medicine Market (by Colorectal Cancer), 2019-2030
Figure 9.5: Global Oncology Precision Medicine Market (by Prostate Cancer), 2019-2030
Figure 9.6: Global Oncology Precision Medicine Market (by Cervical Cancer), 2019-2030
Figure 9.7: Global Oncology Precision Medicine Market (by Other Cancer), 2019-2030
Figure 10.1: Global Oncology Precision Medicine Market (by Ecosystem)
Figure 10.2: Precision Medicine: The Ecosystem
Figure 10.3: Global Oncology Precision Medicine Market (by Applied Sciences)
Figure 10.4: Global Oncology Precision Medicine Market (by Applied Sciences), 2019-2030
Figure 10.5: Global Oncology Precision Medicine Applied Sciences Market Share (by Type), 2019-2030
Figure 10.6: Global Oncology Precision Medicine Genomics Market, 2019-2030
Figure 10.7: Global Oncology Precision Medicine Genomics Market Share (by Technology)
Figure 10.8: Global Oncology Precision Medicine PCR Market, 2019-2030
Figure 10.9: Global Oncology Precision Medicine NGS Market, 2019-2030
Figure 10.10: Global Oncology Precision Medicine Genome Editing Market, 2019-2030
Figure 10.11: Global Oncology Precision Medicine Other Technologies Market, 2019-2030
Figure 10.12: Global Oncology Precision Medicine Pharmacogenomics Market, 2019-2030
Figure 10.13: Global Oncology Precision Medicine Other Applied Sciences Market, 2019-2030
Figure 10.14: Global Oncology Precision Medicine Market (by Precision Diagnostics)
Figure 10.15: Global Oncology Precision Medicine Market (by Precision Diagnostics), 2019-2030
Figure 10.16: Global Oncology Precision Medicine Diagnostics Market Share (by Type), 2019-2030
Figure 10.17: Global Oncology Precision Medicine Molecular Diagnostics Market, 2019-2030
Figure 10.18: Global Oncology Precision Medicine Medical Imaging Market, 2019-2030
Figure 10.19: Global Oncology Precision Medicine Digital Health and Information Technology Market, 2019-2030
Figure 10.20: Global Oncology Precision Medicine Digital Health and Information Technology Market Share (by Type), 2019-2030
Figure 10.21: Global Oncology Precision Medicine CDSS Market, 2019-2030
Figure 10.22: Global Oncology Precision Medicine Big Data Analytics Market, 2019-2030
Figure 10.23: Global Oncology Precision Medicine IT Infrastructure Market, 2019-2030
Figure 10.24: Global Oncology Precision Medicine Genomics Informatics Market, 2019-2030
Figure 10.25: Global Oncology Precision Medicine In-Silico Informatics Market, 2019-2030
Figure 10.26: Global Oncology Precision Medicine Mobile Health Market, 2019-2030
Figure 10.27: Global Oncology Precision Medicine Therapeutics Market, 2019-2030
Figure 10.28: Global Oncology Precision Medicine Therapeutics Market Share (by Type), 2019-2030
Figure 10.29: Global Oncology Precision Medicine Clinical Trials Market, 2019-2030
Figure 10.30: Global Oncology Precision Medicine Cell Therapy Market, 2019-2030
Figure 10.31: Global Oncology Precision Medicine Drug Discovery and Research Market, 2019-2030
Figure 10.32: Types of Gene Therapy
Figure 10.33: Global Oncology Precision Medicine Gene Therapy Market, 2019-2030
Figure 11.1: Global Oncology Precision Medicine Market (by Region)
Figure 11.2: North America Global Oncology Precision Medicine Market, 2019-2030
Figure 11.3: North America: Market Dynamics
Figure 11.4: North America Global Oncology Precision Medicine Market (by Country), 2019-2030
Figure 11.5: U.S. Oncology Precision Medicine Market, 2019-2030
Figure 11.6: Canada Oncology Precision Medicine Market, 2019-2030
Figure 11.7: Europe Oncology Precision Medicine Market, 2019-2030
Figure 11.8: Europe: Market Dynamics
Figure 11.9: Europe Oncology Precision Medicine Market (by Country), 2019-2030
Figure 11.10: Germany Oncology Precision Medicine Market, 2019-2030
Figure 11.11: France Oncology Precision Medicine Market, 2019-2030
Figure 11.12: Italy Oncology Precision Medicine Market, 2019-2030
Figure 11.13: U.K. Oncology Precision Medicine Market, 2019-2030
Figure 11.14: Spain Oncology Precision Medicine Market, 2019-2030
Figure 11.15: Rest-of-Europe Oncology Precision Medicine Market, 2019-2030
Figure 11.16: Asia-Pacific Oncology Precision Medicine Market, 2019-2030
Figure 11.17: Asia-Pacific: Market Dynamics
Figure 11.18: Asia-Pacific Oncology Precision Medicine Market (by Country), 2019-2030
Figure 11.19: China Oncology Precision Medicine Market, 2019-2030
Figure 11.20: Japan Oncology Precision Medicine Market, 2019-2030
Figure 11.21: Australia Oncology Precision Medicine Market, 2019-2030
Figure 11.22: India Oncology Precision Medicine Market, 2019-2030
Figure 11.23: Rest-of-Asia-Pacific Oncology Precision Medicine Market, 2019-2030
Figure 11.24: Latin America Oncology Precision Medicine Market, 2019-2030
Figure 11.25: Latin America: Market Dynamics
Figure 11.26: Latin America Global Oncology Precision Medicine Market (by Country), 2019 and 2030
Figure 11.27: Brazil Oncology Precision Medicine Market, 2019-2030
Figure 11.28: Mexico Oncology Precision Medicine Market, 2019-2030
Figure 11.29: Rest-of-LATAM Oncology Precision Medicine Market, 2019-2030
Figure 11.30: Rest-of-the-World Oncology Precision Medicine Market, 2019-2030
Figure 12.1: Abbott Laboratories: Overall Product Offerings
Figure 12.2: Abbott Laboratories: Overall Financials, 2017-2019
Figure 12.3: Abbott Laboratories: Net Revenue (by Business Segment), 2017-2019
Figure 12.4: Abbott Laboratories: Net Revenue (by Region), 2017-2019
Figure 12.5: Abbott Laboratories: Research and Development Expense, 2017-2019
Figure 12.6: Abbott Laboratories: SWOT Analysis
Figure 12.7: Agilent Technologies, Inc.: Overall Product Offerings
Figure 12.8: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 12.9: Agilent Technologies, Inc.: Net Revenue (by Business Segment), 2017-2019
Figure 12.10: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.11: Agilent Technologies, Inc.: Research and Development Expense, 2017-2019
Figure 12.12: Agilent Technologies, Inc.: SWOT Analysis
Figure 12.13: Almac Group Ltd.: Overall Product Offerings
Figure 12.14: Almac Group Ltd.: SWOT Analysis
Figure 12.15: ANGLE plc: Overall Financials, 2017-2019
Figure 12.16: ANGLE plc: Revenue (by Region), 2018-2019
Figure 12.17: ANGLE plc R&D Expenditure, 2017-2019
Figure 12.18: ANGLE plc: SWOT Analysis
Figure 12.19: ASURAGEN, INC.: Overall Product Offerings
Figure 12.20: ASURAGEN INC.: SWOT Analysis
Figure 12.21: BGI Group.: Overall Product Portfolio
Figure 12.22: BGI Group: SWOT Analysis
Figure 12.23: Bio-Rad Laboratories, Inc: Overall Product Offerings
Figure 12.24: Bio-Rad Laboratories, Inc: Overall Financials, 2017-2019
Figure 12.25: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2017-2019
Figure 12.26: Bio-Rad Laboratories, Inc: Revenue (by Region), 2017-2019
Figure 12.27: Bio-Rad Laboratories, Inc. R&D Expenditure, 2017-2019
Figure 12.28: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 12.29: bioMйrieux S.A.: Overall Product Portfolio
Figure 12.30: bioMйrieux S.A.: Overall Financials, 2017-2019
Figure 12.31: bioMйrieux S.A.: Revenue (by Segment), 2017-2019
Figure 12.32: bioMйrieux S.A.: Revenue (by Region), 2018 and 2019
Figure 12.33: bioMйrieux S.A.: SWOT Analysis
Figure 12.34: Bristol-Myers Squibb Company: Overall Product Portfolio
Figure 12.35: Bristol-Myers Squibb Company: Overall Financials, 2017-2019
Figure 12.36: Bristol-Myers Squibb Company R&D Expenditure, 2017-2019
Figure 12.37: Bristol-Myers Squibb Company: SWOT Analysis
Figure 12.38: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 12.39: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 12.40: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 12.41: Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 12.42: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 12.43: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 12.44: Gilead Sciences, Inc.: Overall Product Portfolio
Figure 12.45: Gilead Sciences, Inc.: Overall Financials, 2017-2019
Figure 12.46: Gilead Sciences, Inc.: R&D Expenditure, 2017-2019
Figure 12.47: Gilead Science, Inc.: SWOT Analysis
Figure 12.48: Illumina, Inc.: Overall Product Portfolio
Figure 12.49: Illumina, Inc.: Overall Financials, 2017-2019
Figure 12.50: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 12.51: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 12.52: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 12.53: Illumina, Inc.: SWOT Analysis
Figure 12.54: Konica Minolta, Inc.: Overall Product Portfolio
Figure 12.55: Konica Minolta, Inc.: Overall Financials, 2017-2019
Figure 12.56: Konica Minolta, Inc.: Revenue (by Region), 2017-2019
Figure 12.57: Konica Minolta, Inc.: Research and Development Expense, 2017-2019
Figure 12.58: Konica Minolta, Inc.: SWOT Analysis
Figure 12.59: Laboratory Corporation of America Holdings.: Overall Product Portfolio
Figure 12.60: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 12.61: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 12.62: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 12.63: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 12.64: MDx Health, Inc.: Overall Financials, 2017--2019
Figure 12.65: MDx Health, Inc.: SWOT Analysis
Figure 12.66: Myriad Genetics, Inc.: Product Portfolio
Figure 12.67: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 12.68: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.69: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 12.70: Myriad Genetics, Inc.: SWOT Analysis
Figure 12.71: Novartis AG: Overall Product Portfolio
Figure 12.72: Novartis AG: Overall Financials, 2017-2019
Figure 12.73: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 12.74: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 12.75: Novartis AG: R& D Expense, 2017-2019
Figure 12.76: Novartis AG: SWOT Analysis
Figure 12.77: OPKO Health, Inc.: Overall Product Portfolio
Figure 12.78: OPKO Health, Inc.: Overall Financials, 2017-2019
Figure 12.79: OPKO Health, Inc: Net Revenue (by Business Segment), 2017-2019
Figure 12.80: OPKO Health, Inc.: Net Revenue (by Region), 2017-2019
Figure 12.81: OPKO Health, Inc.: Research and Development Expense, 2017-2019
Figure 12.82: OPKO Health, Inc.: SWOT Analysis
Figure 12.83: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 12.84: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
Figure 12.85: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019
Figure 12.86: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
Figure 12.87: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
Figure 12.88: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 12.89: Quest Diagnostics Incorporated: Overall Product Offerings
Figure 12.90: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 12.91: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
Figure 12.92: Quest Diagnostics Incorporated: SWOT Analysis
Figure 12.93: QIAGEN N.V.: Overall Product Portfolio
Figure 12.94: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 12.95: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 12.96: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 12.97: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 12.98: QIAGEN N.V.: SWOT Analysis
Figure 12.99: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 12.100: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 12.101: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
Figure 12.102: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 12.103: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 12.104: Thermo Fisher Scientific Inc.: SWOT Analysis
